Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbvie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Abbvie

Revenue up 52% in the quarter to $12.9 billion.

By: Contract Pharma

Contract Pharma Staff

Abbvie

3Q Revenues: $12.9 billion (+52%)

3Q Earnings: $2.3 billion (+23%)

YTD Revenues: $31.9 billion (+30%)

YTD Earnings: $4.6 billion (-10%)

Comments: Revenues from the Immunology Portfolio were $5.8 billion, an increase of 15%. Global Humira revenues were $5.1 billion, up 4%. U.S. Humira revenues were $4.2 billion, up 8%. Internationally, Humira sales were down 9% to $951 million due to biosimilar competition. Global Skyrizi sales were $435 million and Global Rinvoq sales were $215 million in the quarter. Revenues from the Hematologic Oncology Portfolio were $1.7 billion, an increase of 16.5%. Global Imbruvica sales were $1.4 billion, up 9%, with U.S. revenues of $1.1 billion and international profit sharing of $251 million. Global Venclexta sales were $352 million. Revenues from the Aesthetics Portfolio were $967 million. Global Botox Cosmetic revenues were $393 million, down 2%. Revenues from the Neuroscience Portfolio were $1.2 billion, with Global Botox Therapeutic sales of $523 million and Global Vraylar sales of $358 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters